CEGEDIM
Cegedim Relationship Management today announced the availability of the latest release of its global aggregate spend and transparency compliance solution, AggregateSpend360 ™. This new release enables life sciences companies in Europe and the US to meet the most current disclosure obligations imposed by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the US Centers for Medicare and Medicaid Services (CMS).
Keeping Up with Rapidly Changing CMS and EFPIA Disclosure Requirements
The
latest version of AggregateSpend360 provides extensive capability and
flexibility to ensure that manufacturers submit reports based on CMS and
EFPIA guidelines while adhering to their individual corporate practices.
Life sciences companies in the US can utilize AggregateSpend360 to meet
the latest CMS requirements, including the March 31, 2015 deadline for
2014 data submissions. It provides functions to comply with CMS
validated physician and teaching hospital lists and re-submission
requirements; and provides tools to validate submission reports against
CMS rules, special characters and error checking. And for life sciences
companies in Europe, the latest version enables efficient payment data
collection and consent management as required by EFPIA starting on
January 1, 2015.
“In the last few months, we have observed a significant acceleration in the global demand for transparency reporting solutions due to the implementation of the EFPIA code,” stated Dario Ghoddousi, Senior Vice President, Global Transparency and Master Data Management Solutions for Cegedim. “AggregateSpend360 has been selected by several new customers, confirming our leadership position, and pushing us to accelerate the development of the global functionalities that the market expects from us.”
“Cegedim continues to be the leader in global transparency and disclosure solutions by being in the forefront of a rapidly evolving global environment,” stated Don Soong, Vice President of Strategic Solutions for Cegedim Relationship Management. “The latest evolution in AggregateSpend360 not only enables life sciences companies around the world to meet their reporting requirements, but also provides the capability for manufacturers to easily create and verify the accuracy of reports.”
AggregateSpend360, which is being leveraged by more than 60 Life Sciences companies around the world, is an out-of-the-box, cloud-based solution that streamlines the tracking and reporting of expenditures per global, national and local disclosure and transparency requirements – by collecting expenditure transactions, linking them to a single customer view, and automatically generating reports to satisfy unique compliance requirements through prebuilt templates according to each transparency regulation. AggregateSpend360 is pre-integrated with Cegedim’s Compliance ID powered by OneKey, Mobile Intelligence and Nucleus360 solutions. Integration is also available with a wide range of enterprise applications for CRM/SFA, ERP, Finance and HR.
To learn more about AggregateSpend360, please visit the Cegedim website .
About Cegedim Relationship Management:
Cegedim
Relationship Management is the Life Sciences industry’s leading provider
of Customer Relationship Management (CRM) solutions. Designed
specifically for Life Sciences, the company’s innovative business
solutions incorporate a thorough understanding of local, regional and
worldwide trends. Cegedim Relationship Management enables approximately
200,000 users in many of the world’s most innovative companies to stay
ahead of market challenges. In addition to CRM, Cegedim Relationship
Management also provides marketing, data optimization and regulatory
compliance solutions in more than 80 countries. Cegedim Relationship
Management is part of the France-based Cegedim S.A. Group.
To learn more, please visit: www.cegedim.com/rm
.
Follow
Cegedim Relationship Management on LinkedIn
and Twitter
.
About Cegedim:
Founded in 1969, Cegedim is a global
technology and services company specializing in the healthcare field.
Cegedim supplies services, technological tools, specialized software,
data flow management services and databases. Its offerings are targeted
notably at healthcare industries, life sciences companies, healthcare
professionals and insurance companies. The world leader in life sciences
CRM, Cegedim is also one of the leading suppliers of strategic
healthcare industry data. Cegedim employs almost 8,000 people in more
than 80 countries and generated revenue of €912 million in 2014. Cegedim
SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com
.
Follow
Cegedim on Twitter: @CegedimGroup
.
Contact:
Drew BUSTOS,
Tel.: +1 (908) 443.2451
Cegedim Relationship
Management
Global Communications
drew.bustos@cegedim.com
or
Aude
BALLEYDIER,
Tel.: +33 (0)1 49 09 68 81
Cegedim
Media
Relations
aude.balleydier@cegedim.fr
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Fujirebio Receives Marketing Clearance for Lumipulse®G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 08:58:00 CEST | Press release
—First Blood-Based In-Vitro Diagnostic Test to Receive FDA Clearancefor Patients Being Assessed for Alzheimer’s Disease. ——Availability of Accurate, Accessible, Blood-Based Diagnostic Tests Will Aid in Development and Availability of More Effective Interventions for Alzheimer’s Disease — Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause
IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes16.5.2025 23:17:00 CEST | Press release
IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% Senior Notes due 2027 (the “2027 Notes”), 4.450% Senior Notes due 2028 (the “2028 Notes”) and 2.300% Senior Notes due 2030 (the “2030 Notes” and collectively with the 2025 Notes, the 2027 Notes and the 2028 Notes, the “Pool 1 Notes”) and (ii) up to $900,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 2 Maximum Amount” and, together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), of its 3.268% Senior Notes due 2040 (the “2040 Notes”), 4.375% Senior Notes due 2047 (the “2047 Notes”), 5.000% Senior Notes due 2048 (the “2048 Notes”) and 3.468% Senior Notes due 2050 (the “2050
Origins Launches in the U.S. Amazon Premium Beauty Store16.5.2025 15:00:00 CEST | Press release
The brand brings its high-performance, clinically proven, nature-inspired skincare to Amazon shoppers Origins, with over 30 years of expertise in combining naturally-derived and scientifically crafted ingredients for powerful skincare, announced its official debut in the U.S. Amazon Premium Beauty store today. Origins will offer its iconic skincare and body care products along with giftable sets that are perfect for any occasion. Origins will now bring naturally-derived, effective beauty to Amazon customers nationwide with convenience and thoughtful gifting in mind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250516435958/en/ This launch marks a strategic step in Origins’ ongoing efforts to meet the evolving needs of skincare shoppers, seeking high-performance, conscious beauty on their favorite platforms. By expanding to the U.S. Amazon Premium Beauty store, Origins reinforces its commitment to delivering both efficacy a
The smarter E Europe 2025: Studies, Technologies and Market Trends for the Energy System of Tomorrow16.5.2025 12:47:00 CEST | Press release
Exactly one week has passed since The smarter E Europe closed its doors in Munich. Once again, Europe’s largest alliance of exhibitions for the energy industry turned the Bavarian capital into the epicenter of the global energy sector and impressed with outstanding results. Over the course of three days, 2,737 exhibitors from 57 countries showcased their technologies, business models and market-ready solutions for an intelligent, interconnected and fully renewable energy system. Around 107,000 professionals from 157 nations took the opportunity to connect, initiate partnerships and launch new projects. The accompanying conferences and side events also attracted strong interest, drawing more than 2,600 participants. The message sent out by The smarter E Europe and its four exhibitions – Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe – was clear: We are the energy system. This press release features multimedia. View the full release here: https://www.businesswire.c
IFF Announces Early Tender Results and Increase of Tender Offers for Certain Outstanding Series of Notes16.5.2025 12:30:00 CEST | Press release
IFF (NYSE: IFF) announced today the early tender results for its tender offers to purchase for cash certain of its outstanding series of Notes. IFF also announced it has increased the previously announced Pool 1 Maximum Amount (as defined below) from $1,000,000,000 to $1,100,000,000 (the “Amended Pool 1 Maximum Amount”), the Pool 2 Maximum Amount (as defined below) from $800,000,000 to $900,000,000 (the “Amended Pool 2 Maximum Amount”, and together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), the 2027 Series Tender Cap (as defined below) from $300,000,000 to $400,000,000 and the 2050 Series Tender Cap (as defined below) from $600,000,000 to $649,114,000. The 2025 Notes Series Tender Cap and the 2040 Notes Series Tender Cap (each as defined below) remain unchanged at $500,000,000 and $450,000,000, respectively. Details of tender offers IFF initially offered to purchase for cash: (i) up to $1,000,000,000 aggregate purchase price, excluding accrued and unpaid in
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum